Compile Data Set for Download or QSAR
maximum 50k data
Found 314 Enz. Inhib. hit(s) with all data for entry = 10229
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521573(US11149054, Compound 5)
Affinity DataEC50:  260nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521574(US11149054, Compound 6)
Affinity DataEC50:  248nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521574(US11149054, Compound 6)
Affinity DataEC50:  733nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521575(US11149054, Compound 11)
Affinity DataEC50:  117nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521575(US11149054, Compound 11)
Affinity DataEC50:  104nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521576(US11149054, Compound 2080)
Affinity DataEC50:  165nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521576(US11149054, Compound 2080)
Affinity DataEC50:  187nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521577(US11149054, Compound 2081)
Affinity DataEC50:  129nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521577(US11149054, Compound 2081)
Affinity DataEC50:  175nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521578(US11149054, Compound 2184)
Affinity DataEC50:  65.8nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521578(US11149054, Compound 2184)
Affinity DataEC50:  80nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521579(US11149054, Compound 2285)
Affinity DataEC50:  764nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521579(US11149054, Compound 2285)
Affinity DataEC50:  494nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521580(US11149054, Compound 2392)
Affinity DataEC50:  104nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521580(US11149054, Compound 2392)
Affinity DataEC50:  47.5nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521581(US11149054, Compound 2499)
Affinity DataEC50:  768nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521581(US11149054, Compound 2499)
Affinity DataEC50:  751nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521582(US11149054, Compound 2500)
Affinity DataEC50:  63.3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521582(US11149054, Compound 2500)
Affinity DataEC50:  91.1nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521583(US11149054, Compound 2602)
Affinity DataEC50:  289nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521583(US11149054, Compound 2602)
Affinity DataEC50:  279nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521584(US11149054, Compound 2706)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521584(US11149054, Compound 2706)
Affinity DataEC50:  124nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521585(US11149054, Compound 2707)
Affinity DataEC50:  119nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521585(US11149054, Compound 2707)
Affinity DataEC50:  103nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521586(US11149054, Compound E-2817)
Affinity DataEC50:  5.07E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521586(US11149054, Compound E-2817)
Affinity DataEC50:  5.37E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521587(US11149054, Compound 2918)
Affinity DataEC50:  298nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521587(US11149054, Compound 2918)
Affinity DataEC50:  339nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521588(US11149054, Compound 3035)
Affinity DataEC50:  61nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521588(US11149054, Compound 3035)
Affinity DataEC50:  75.7nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521589(US11149054, Compound 3149)
Affinity DataEC50:  69.7nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521589(US11149054, Compound 3149)
Affinity DataEC50:  60.7nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521590(US11149054, Compound 3266)
Affinity DataEC50:  148nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521590(US11149054, Compound 3266)
Affinity DataEC50:  377nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521591(US11149054, Compound 3382)
Affinity DataEC50:  67.6nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521591(US11149054, Compound 3382)
Affinity DataEC50:  126nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521592(US11149054, Compound 3495)
Affinity DataEC50:  96.7nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521592(US11149054, Compound 3495)
Affinity DataEC50:  168nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521593(US11149054, Compound 3496)
Affinity DataEC50:  35.1nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521593(US11149054, Compound 3496)
Affinity DataEC50:  47.6nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521594(US11149054, Compound 3507)
Affinity DataEC50:  165nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521594(US11149054, Compound 3507)
Affinity DataEC50:  191nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521595(US11149054, Compound 3634)
Affinity DataEC50:  423nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521595(US11149054, Compound 3634)
Affinity DataEC50:  404nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521596(US11149054, Compound 3788)
Affinity DataEC50:  1.32E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521596(US11149054, Compound 3788)
Affinity DataEC50:  1.12E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521597(US11149054, Compound 3877)
Affinity DataEC50: >1.00E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521597(US11149054, Compound 3877)
Affinity DataEC50:  512nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Sage Therapeutics

US Patent
LigandPNGBDBM521598(US11149054, Compound 3983)
Affinity DataEC50:  88.1nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 314 total ) | Next | Last >>
Jump to: